| In millions, except per share items | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 | Dec-31-14 |
| | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K | 10-K |
| OPERATING CASH FLOW | | | | | | | | |
| Net earnings (loss) | -401.7 | -366.8 | -1,553.1 | 232.9 | 264.5 | 327.4 | 475.0 | 647.5 |
| |
| Adjustments to reconcile net earnings to operating cash flow: | | | | | | | | |
| Impairment | 290.1 | 443.3 | 383.0 | | | | | |
| (Earnings) loss from equity method investments, net of distributions | -7.8 | -3.9 | 9.3 | 1.0 | 2.8 | 12.2 | -1.6 | 1.3 |
| Loss (gain) on sales of assets (including AMECO-South America in 2023) | -2.2 | -0.5 | 7.3 | -147.1 | -22.7 | -21.6 | -31.3 | -33.9 |
| Stock-based compensation | 32.0 | 21.9 | 36.1 | 43.0 | 40.7 | 40.1 | 61.1 | 48.2 |
| Deferred taxes | 28.6 | -20.3 | 320.6 | 60.7 | 100.3 | -7.9 | 4.7 | 62.1 |
| Changes in assets and liabilities | -196.7 | 31.0 | 631.7 | -227.7 | | | | |
| Other | 3.3 | -3.3 | -5.6 | 3.5 | 8.8 | 2.5 | -5.4 | 0.3 |
| Operating cash flow | 25.3 | 185.9 | 219.0 | 162.2 | 602.0 | 705.9 | 849.1 | 642.6 |
| |
| INVESTING CASH FLOW | | | | | | | | |
| Purchases of marketable securities | -148.5 | -35.1 | -31.2 | -483.5 | -237.4 | -360.0 | -386.0 | -410.5 |
| Proceeds from the sales and maturities of marketable securities | 44.7 | 19.6 | 238.5 | 541.1 | 216.4 | 522.1 | 411.4 | 419.4 |
| Capital expenditures | -75.1 | -113.4 | -180.8 | -211.0 | -283.1 | -235.9 | -240.2 | -324.7 |
| Proceeds from sales of assets (including AMECO-South America in 2023) | 145.7 | 111.6 | 66.0 | 81.0 | 96.1 | 81.2 | 94.3 | 105.9 |
| Investments in partnerships and joint ventures | -79.5 | -29.2 | -52.3 | -73.1 | | | | -38.7 |
| Other | -9.2 | 4.9 | 40.3 | -1.4 | -6.5 | 6.5 | 17.5 | 5.5 |
| Investing cash flow | -121.9 | -41.6 | 80.5 | 1.4 | -484.3 | -741.4 | -66.5 | -199.1 |
| |
| FINANCING CASH FLOW | | | | | | | | |
| Dividends paid on CPS | | | | -118.7 | -118.0 | -118.0 | | |
| Distributions paid to NCI | -108.8 | -23.2 | -33.7 | -63.5 | -47.2 | -57.9 | -59.0 | -138.0 |
| Capital contributions by NCI | 201.8 | 110.1 | 64.6 | 5.1 | 6.4 | 9.1 | 5.3 | 3.3 |
| Taxes paid on vested restricted stock | | | | -5.7 | -6.2 | -7.0 | -8.4 | -11.5 |
| Other | -1.4 | -13.6 | 0.7 | -8.5 | -6.4 | -11.4 | -4.6 | -3.0 |
| Financing cash flow | 122.3 | 48.4 | -77.3 | -140.5 | -215.5 | -10.4 | -728.2 | -666.4 |
| Effect of exchange rate changes on cash | -15.1 | 8.8 | 10.3 | -62.4 | | | | |
| Increase (decrease) in cash and cash equivalents | 10.6 | 201.6 | 232.5 | -39.3 | | | | |